Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inlexisertib
- Development stage
- Phase 2
- Lead developer
- Deciphera Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Inlexisertib is an orally bioavailable, selective small molecule inhibitor of the serine/threonine-protein kinases **ULK1** and **ULK2**, developed for the potential treatment of various cancers. It inhibits autophagosome formation by suppressing phosphorylation of ULK1/2 substrates such as ATG13, thereby blocking autophagy. This mechanism is particularly relevant in tumors, such as mutant RAS cancers, that depend on autophagy for survival and drug resistance. Inlexisertib is in clinical development, investigated both as monotherapy and in combination with other targeted anticancer agents such as trametinib, binimetinib, sotorasib, and ripretinib for a range of solid tumors, including gastrointestinal stromal tumors and KRAS mutant cancers[1][2][3][5][7][9].
- Other names
- inlexisertib [INN]2543673-19-2
02
Targets
ULK2 (Unc-51-like kinase 2)
Beyond the preview
Go deeper on inlexisertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inlexisertib.